Global Stroke Prevention in Atrial Fibrillation Market 2016 - Which Patient Subgroups and Markets will have the Largest Impact on SPAF Sales? - Research and Markets

DUBLIN, August 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Stroke Prevention in Atrial Fibrillation" report to their offering.

The value of the stroke prevention in atrial fibrillation (SPAF) market is expected to grow rapidly as novel oral anticoagulant (NOAC) class molecules secure approvals of their antidotes and physician acceptance of these drugs rises.

This report addresses the following questions:

- Which patient subgroups and markets will have the largest impact on SPAF sales?

- How will the approval of antidotes affect uptake of the NOAC class?

- Will Savaysa's recent approval for SPAF have a significant effect on the market dynamics?

- What are the most commonly prescribed therapies for stroke prevention in both valvular and non-valvular atrial fibrillation patients?

- What are the most important factors influencing prescribing trends?

- How do prescribing trends correlate with current recommendations from clinical guidelines?

Key Topics Covered:

FORECAST: STROKE PREVENTION IN ATRIAL FIBRILLATION

- Executive Summary

- Market Overview and Trends

- Market Definition and Methodology

- Eliquis (apixaban)

- Pradaxa (dabigatran)

- Savaysa (edoxaban)

- Xarelto (rivaroxaban)

- Primary Research Methodology

TREATMENT: STROKE PREVENTION IN ATRIAL FIBRILLATION

- Executive Summary

- Primary Research Methodology

- Disease Definition and Diagnosis

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

EPIDEMIOLOGY: ATRIAL FIBRILLATION

- Executive Summary

- Disease Background

- Sources and Methodology

- Forecast

- Epidemiologist Insight

- Strengths and Limitations

MARKETED DRUGS: STROKE PREVENTION IN ATRIAL FIBRILLATION

- Executive Summary

- Product Overview

- Product profile: Eliquis

- Product profile: Pradaxa

- Product profile: Savaysa

- Product profile: Xarelto

PIPELINE: STROKE PREVENTION IN ATRIAL FIBRILLATION

- Executive Summary

- Pipeline Trends

For more information visit http://www.researchandmarkets.com/research/djsc9x/stroke_prevention

Media Contact:

Laura Wood, Senior Manager

[email protected] 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com